You are currently viewing a new version of our website. To view the old version click .
Clinics and Practice
  • Clinics and Practice is published by MDPI from Volume 11 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
  • Case Report
  • Open Access

23 November 2011

Long-Term Reversibility of Renal Dysfunction Associated to Light Chain Deposition Disease with Bortezomib and Dexamethasone and High Dose Therapy and Autologous Stem Cell Transplantation

,
,
,
and
1
Hematology Department, Salamanca, Spain
2
Pathology Service, University Hospital of Salamanca, Salamanca, Spain
*
Author to whom correspondence should be addressed.

Abstract

A 63-year-old woman presented with progressive renal insufficiency, until a glomerular filtration rate (GFR) of 12 mL/min. A renal biopsy demonstrated glomerular deposition of immunoglobulin k light chain. The presence of a small population of monoclonal plasmacytes producing an only light k monoclonal component was demonstrated and Bortezomib and Dexamethasone (BD) was provided as initial therapy. After seven courses of therapy, renal function improved without dialysis requirements up to a GFR 31 mL/min. Under hematological complete response (HCR) the patient underwent high dose of melphalan (HDM) and autologous peripheral blood stem cell transplant. Fifty-four months later the patient remains in HCR and the GFR has progressively improved up to 48 mL/min. This report describes a notably renal function improvement in a patient with Light Chain Deposition Disease after therapy with BD followed by HDM, which can support this treatment as a future option for these patients.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.